发帖
每发1个新帖
可以获得0.5个丁当奖励
回帖

【medical-news】年轻的骨髓增生异常综合征患者死亡率低

只看楼主
页码直达：
直达末页

楼主

蓝色幻想

心血管内科

丁香园中级站友

1楼

这个帖子发布于13年零63天前，其中的信息可能已发生改变或有所发展。

Myelodysplastic Syndromes Less Deadly in the Young

NEW YORK (Reuters Health) Dec 18 - Many patients with myelodysplastic syndromes (MDS), particularly younger patients in lower risk groups, are unlikely to benefit from aggressive treatment such allogeneic stem-cell transplantation, German researchers report in the December 1st issue of the Journal of Clinical Oncology.

Dr. Andrea Kuendgen, and colleagues at Heinrich-Heine-University, Dusseldorf note that MDS mainly affects the elderly. However, the researchers evaluated younger patients to see if any might be suitable candidates for allogeneic stem-cell transplantation. This potentially curative approach carries a high risk of treatment-related complications.

The team examined data on 232 patients less than 50 years old and compared their outcomes with those in 2496 older patients. The younger patients comprised 8.5% of the cohort, a proportion, similar to that seen in other studies.

Survival was significantly longer in the younger group (40 months) than in the older group (23 months). However, this difference was observed only in patients belonging to the low- and intermediate-I-risk categories of the International Prognostic Scoring System. Survival was identical (8 months in both groups) in the intermediate-II and high-risk categories.

The investigators add that there was a particularly large difference in median survival time between the intermediate-I and intermediate-II risk groups (176 months versus 8 months). For low-risk patients, the overall survival rate was more than 86% at 20 years.

Thus the researchers conclude that "aggressive treatment approaches should rarely be recommended to younger MDS patients in the low- and intermediate-I-risk groups."

http://www.medscape.com/viewarticle/549573

邀请讨论

搜索

2006-12-20 02:24 浏览 : 830 回复 : 3

投票
收藏 1
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

• 全国急招医护技岗位汇总，大专以上可投

xujianhua50

中医肿瘤科

铁杆站友

2楼

本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。

2006-12-20 09:25

投票
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

• 关于山东大学在职博士研究生论文单位署名的通知

xujianhua50

中医肿瘤科

铁杆站友

3楼

NEW YORK (Reuters Health) Dec 18 - Many patients with myelodysplastic syndromes (MDS), particularly younger patients in lower risk groups, are unlikely to benefit from aggressive treatment such allogeneic stem-cell transplantation, German researchers report in the December 1st issue of the Journal of Clinical Oncology.
纽约（路透社）12月18日-，德国的研究人员在临床肿瘤杂志12月1日版上报道，许多骨髓增生异常综合征(MDS)患者，特别是低风险的年轻患者，不大可能从干细胞异体移植等强力治疗中获益。
Dr. Andrea Kuendgen, and colleagues at Heinrich-Heine-University, Dusseldorf note that MDS mainly affects the elderly. However, the researchers evaluated younger patients to see if any might be suitable candidates for allogeneic stem-cell transplantation. This potentially curative approach carries a high risk of treatment-related complications.
德国杜塞尔多夫海涅大学Andrea Kuendgen博士及其同事注意到，MDS主要侵犯老年人。不过研究人员对年轻患者进行评估，看是否任何人都适合干细胞异体移植。这种有治愈可能的措施带来了很高的与治疗相关的合并症风险。
The team examined data on 232 patients less than 50 years old and compared their outcomes with those in 2496 older patients. The younger patients comprised 8.5% of the cohort, a proportion, similar to that seen in other studies.
研究小组对232名小于50岁的患者进行了研究，并与2496例年老患者进行比较。年轻患者占8.5%，比例与其他研究相类似。
Survival was significantly longer in the younger group (40 months) than in the older group (23 months). However, this difference was observed only in patients belonging to the low- and intermediate-I-risk categories of the International Prognostic Scoring System. Survival was identical (8 months in both groups) in the intermediate-II and high-risk categories.
生存期年轻患者为40个月，年老患者为23个月，年轻患者明显延长。不过，这种差异仅在国际预后评分系统属于低中I风险的患者中看到。在中II和更高风险类别中，生存期相同，二组都为8个月。
The investigators add that there was a particularly large difference in median survival time between the intermediate-I and intermediate-II risk groups (176 months versus 8 months). For low-risk patients, the overall survival rate was more than 86% at 20 years.
研究人员补充道，在中I和中II风险组之间，中位生存期有特别大的差异，达到176个月对8个月。对于低风险患者，20年的总的生存率超过86%。
Thus the researchers conclude that "aggressive treatment approaches should rarely be recommended to younger MDS patients in the low- and intermediate-I-risk groups."
因此研究人员总结道：“强力治疗措施应该很少被推荐到低中I风险的年轻MDS患者。”

2006-12-20 21:28

投票
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

xujianhua50 编辑于 2006-12-20 21:36

• 四川这样关怀一线医生，你们不来抄袭一下吗？

xujianhua50

中医肿瘤科

铁杆站友

4楼

纽约（路透社）12月18日报道，德国的研究人员在12月1日版的临床肿瘤杂志上报道，许多骨髓增生异常综合征(MDS)患者，特别是低风险的年轻患者，很少能从干细胞异体移植等强力治疗中获益。
德国杜塞尔多夫海涅大学Andrea Kuendgen博士及其同事注意到，MDS主要侵犯老年人。不过研究人员对年轻患者进行评估，看是否适合干细胞异体移植。但是这种有治愈可能的措施却带来了很大的合并症风险。
研究小组对232名小于50岁的患者进行了研究，并与2496例年老患者进行比较。年轻患者占8.5%，比例与其他研究相类似。
生存期年轻患者为40个月，年老患者为23个月，年轻患者明显延长。不过，这种差异仅在国际预后评分系统属于低、中I风险的患者中看到。在中II和更高风险类别中，二组生存期相同，都为8个月。
研究人员补充道，在中I和中II风险组之间，中位生存期差异特别大，达到176个月对8个月。对于低风险患者，20年的总的生存率超过86%。
研究人员总结道：“强力治疗措施应该很少被推荐到低、中I风险的年轻MDS患者。”

2006-12-20 21:39

投票
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

• 【述评】新型冠状病毒肺炎患者围手术期处理及防护的认识与思考

科技动态

【medical-news】年轻的骨髓增生异常综合征患者死亡率低

提示

丁香园旗下网站

关于丁香园

官方链接

科技动态

分享到：

微信扫一扫

【medical-news】年轻的骨髓增生异常综合征患者死亡率低

微信扫一扫

微信扫一扫

微信扫一扫

微信扫一扫

提示

丁香园旗下网站

关于丁香园

官方链接